vs
Amphastar Pharmaceuticals, Inc.（AMPH）与GDEV Inc.（GDEV）财务数据对比。点击上方公司名可切换其他公司
Amphastar Pharmaceuticals, Inc.的季度营收约是GDEV Inc.的1.5倍（$183.1M vs $119.9M），GDEV Inc.净利率更高（13.9% vs 13.3%，领先0.5%），GDEV Inc.同比增速更快（13.3% vs -1.8%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
GDEV Inc.是一家游戏娱乐控股公司，在纳斯达克上市，总部位于塞浦路斯利马索尔。该公司前身为2014年成立的游戏公司Nexters，2023年6月改组为控股集团，是欧洲前五的独立移动游戏企业，旗下拥有Nexters Studio、Cubic Games、Royal Ark、Game Gears、Light Hour Games等工作室，分支机构分布在塞浦路斯、亚美尼亚、哈萨克斯坦等地。
AMPH vs GDEV — 直观对比
营收规模更大
AMPH
是对方的1.5倍
$119.9M
营收增速更快
GDEV
高出15.1%
-1.8%
净利率更高
GDEV
高出0.5%
13.3%
损益表 — Q4 FY2025 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $119.9M |
| 净利润 | $24.4M | $16.6M |
| 毛利率 | 46.8% | — |
| 营业利润率 | 19.4% | 15.5% |
| 净利率 | 13.3% | 13.9% |
| 营收同比 | -1.8% | 13.3% |
| 净利润同比 | -35.7% | 13.0% |
| 每股收益（稀释后） | $0.51 | $0.90 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHGDEV
| Q4 25 | $183.1M | — | ||
| Q3 25 | $191.8M | — | ||
| Q2 25 | $174.4M | $119.9M | ||
| Q1 25 | $170.5M | — | ||
| Q4 24 | $186.5M | — | ||
| Q3 24 | $191.2M | — | ||
| Q2 24 | $182.4M | $105.8M | ||
| Q1 24 | $171.8M | — |
净利润AMPHGDEV
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | — | ||
| Q2 25 | $31.0M | $16.6M | ||
| Q1 25 | $25.3M | — | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | — | ||
| Q2 24 | $37.9M | $14.7M | ||
| Q1 24 | $43.2M | — |
毛利率AMPHGDEV
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
营业利润率AMPHGDEV
| Q4 25 | 19.4% | — | ||
| Q3 25 | 13.2% | — | ||
| Q2 25 | 24.2% | 15.5% | ||
| Q1 25 | 21.9% | — | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 29.8% | — | ||
| Q2 24 | 30.3% | 14.4% | ||
| Q1 24 | 27.9% | — |
净利率AMPHGDEV
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | — | ||
| Q2 25 | 17.8% | 13.9% | ||
| Q1 25 | 14.8% | — | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | — | ||
| Q2 24 | 20.8% | 13.9% | ||
| Q1 24 | 25.1% | — |
每股收益（稀释后）AMPHGDEV
| Q4 25 | $0.51 | — | ||
| Q3 25 | $0.37 | — | ||
| Q2 25 | $0.64 | $0.90 | ||
| Q1 25 | $0.51 | — | ||
| Q4 24 | $0.74 | — | ||
| Q3 24 | $0.78 | — | ||
| Q2 24 | $0.73 | $0.81 | ||
| Q1 24 | $0.81 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $41.6M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $-129.4M |
| 总资产 | $1.6B | $210.2M |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHGDEV
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | — | ||
| Q2 25 | $231.8M | $41.6M | ||
| Q1 25 | $236.9M | — | ||
| Q4 24 | $221.6M | — | ||
| Q3 24 | $250.5M | — | ||
| Q2 24 | $217.8M | $50.8M | ||
| Q1 24 | $289.6M | — |
总债务AMPHGDEV
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHGDEV
| Q4 25 | $788.8M | — | ||
| Q3 25 | $776.7M | — | ||
| Q2 25 | $757.5M | $-129.4M | ||
| Q1 25 | $751.3M | — | ||
| Q4 24 | $732.3M | — | ||
| Q3 24 | $727.7M | — | ||
| Q2 24 | $713.3M | $-118.7M | ||
| Q1 24 | $672.4M | — |
总资产AMPHGDEV
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $1.6B | $210.2M | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | $282.8M | ||
| Q1 24 | $1.6B | — |
负债/权益比AMPHGDEV
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | — |
| 自由现金流经营现金流 - 资本支出 | $24.6M | — |
| 自由现金流率自由现金流/营收 | 13.4% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | — |
8季度趋势，按日历期对齐
经营现金流AMPHGDEV
| Q4 25 | $32.9M | — | ||
| Q3 25 | $52.6M | — | ||
| Q2 25 | $35.6M | — | ||
| Q1 25 | $35.1M | — | ||
| Q4 24 | $29.0M | — | ||
| Q3 24 | $60.0M | — | ||
| Q2 24 | $69.1M | — | ||
| Q1 24 | $55.3M | — |
自由现金流AMPHGDEV
| Q4 25 | $24.6M | — | ||
| Q3 25 | $47.2M | — | ||
| Q2 25 | $25.0M | — | ||
| Q1 25 | $24.4M | — | ||
| Q4 24 | $16.6M | — | ||
| Q3 24 | $46.2M | — | ||
| Q2 24 | $63.1M | — | ||
| Q1 24 | $46.5M | — |
自由现金流率AMPHGDEV
| Q4 25 | 13.4% | — | ||
| Q3 25 | 24.6% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.3% | — | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 24.1% | — | ||
| Q2 24 | 34.6% | — | ||
| Q1 24 | 27.1% | — |
资本支出强度AMPHGDEV
| Q4 25 | 4.5% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 6.3% | — | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 7.2% | — | ||
| Q2 24 | 3.3% | — | ||
| Q1 24 | 5.1% | — |
现金转化率AMPHGDEV
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
GDEV
暂无分部数据
